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Immunosuppression of canine, monkey, and 
baboon allografts by FK 506: with special 
reference to synergism with other drugs and 
to tolerance induction 
S. Todo, Y. Ueda, J. A. Demetris, O. Imventarza, M. Nalesnik, 
R. Venkataramanan, L. Makowka, and T. E. Starzl, MD,· Pittsburgh, Pa. 
In dogs the most effective oral dose of FK 506 for prevention of renal homograft 
rejection was 1.5 mg/kg/day. With maximum credit allowed at 90 days, survival was 
increased to 61.0 ± 33.6 (SD) days compared with 73.0 ± 4.1 in untreated control 
animals. Higher doses were toxic. The smallest dose that was used (0.5 mg/kg/day) 
prolonged survival after renal transplantation to 33.7 ± 23.9 (SD) days. When the 
small dose of FK 506 was combined with 5 mg/kg/day of cyclosporine and 5 mg of 
prednisone, five of six canine kidney recipients lived for 90 days. These results were 
degraded by omission of any of the constituent drugs or reduction by half of the triple 
drug doses. Thirteen of the dogs treated with various drug regimens lived for 90 days, 
after which time treatment was stopped; 10 of the dogs eventually rejected the grafts, 
but three had continued graft function for 6 months or longer and may be permanently 
tolerant. Moreover, in dogs when 1 mg/kg of intramuscular FK was given to 19 
kidney and seven liver recipients for 3 days on postoperative days 1 to 3, 4 to 6, or 7 
to 9, the animals survived subsequently for 17 to more than 160 days. All but four of 
the grafts were eventually rejected, but the prolonged effect of a short course of delayed 
therapy suggests the possibility of tolerance induction. In cynomolgus monkeys and 
baboons, FK as a single drug was found to be immunosuppressive after kidney 
transplantation. Correlation in the dogs and primates between immunosuppression, 
toxicity, and FK blood levels was not possible because of presently imperfect 
standardization of assay and monitoring techniques. FK had serious side effects in dogs, 
but not so obviously in monkeys and not at all in baboons. (SURGERY 
1988; 104:239-49.) 
From the Department of Surgery, University of Pittsburgh Health Center, University of 
Pittsburgh, and the Veterans Administration Medical Center, Pittsburgh, Pa. 
FK 506, A POWERFUL new immunosuppressive agent, 
was discovered in Japan less than 4 years ago and 
reported in the literature for the first time in 1987.1•11 
Within a few months of the first report, an internation-
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al symposium was held in Sweden, at which time 
everything known about FK 506 as of June 1987 was 
discussed.12 Despite the intensity of these efforts, 
important issues remain upresolved. The questions 
concern the therapeutic efficacy of the agent when used 
alone or in combination with other drugs, its toxicity, 
and its pharmacologic monitoring. 
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An effort is made here to clarify these issues in dogs 
and subhuman primates. The principal inquiries in the 
canine experiments concerned the use of small doses of 
FK 506 in combination with subtherapeutic doses of 
other conventional agents or the use of large doses for 
tolerance induction. In cynomolgus monkeys and 
baboons, the efficacy and toxicity of long-term FK 
alone were studied. In all three species, an effort was 
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Table I. Canine experimental groups 
Group n 
Oral FK dose 
(mg/kg/day) 
Oral CyA 
(mg/kg/day) 
Renal transplantation in dogs with oral FK 506 
1 6 
2 6 0.5 
3 6 1.0 
4 6 1.5 
5 6 2.0 
6 6 0.5 5 
7 6 0.25 2.5 
8 6 0.5 5 
9 5 0.5 
10 6 5 
11 6 5 
12 5 
Renal transplantation in dogs with FK 506 1M 
13 6 
14 4 
15 6 
16 3 
Liver transplantation in dogs with FK 506 1M 
17 3 
18 4 
Legend: M, Mongrel; B, beagle; eyA, cyclosporine; 1M, intramuscularly. 
made to correlate the results with blood levels of the 
drug with the use of newly developed assay tech-
niques. 
METHODS 
Animal and operative procedures 
Dogs. With a few exceptions that will be specifically 
noted, fasted mongrel dogs were used for donors and 
beagles were used as recipients. Weights were 10 to 13 
kg. Anesthesia was induced with 25 mg/kg of intrave-
nous pentobar6ital, adding supplementary pentobarbi-
tal, 2 mg/kg of ketamine, or both when needed. One 
gram per day of cephalosporin was given for 3 days to 
the kidney recipients and for 5 days to the liver 
recipients. All animals were started on a diet ad libitum 
on the first postoperative day. 
Most of the experiments were with kidney trans-
plantation (Table I). The donor kidney from a mongrel 
donor was placed in the right iliac fossa of the recipient, 
anastomosing the renal artery to the proximal end of 
the transected common iliac artery, the renal vein to the 
side of the common iliac vein, and the ureter to the 
bladder. Bilateral recipient nephrectomy was per-
formed. 
In the dogs receiving FK only (groups 2 to 5), the 
doses listed in Table I were reduced after 2 months to 
Prednisone 
(mg/day) 
5 
1M FK, 1/mg/kg 
(on postop days shown) 
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Donor recipient 
2.5 
M-B 
M-B 
M-B 
M-B 
M-B 
M-B 
M-B 
M-B 
M-B 
M-B 
M-B 
M-B 
5 
5 
5 
1,2,3 
4,5,6 
7,8,9 
4,5,6;31,32 
4,5,6 
4,5,6 
M-B 
M-B 
M-B 
M-B 
B-B 
M-B 
75%. In all dogs all therapy was stopped after 90 
days. 
Orthotopic liver transplantation was performed in 
dogs weighing 10 to 15 kg with the aid of a heparin-
free venovenous bypass.13 The liver transfer was from 
mongrel donor to beagle recipient in four experiments 
and from beagle to beagle in three (Table I). 
Subhuman primates. All experiments were with 
renal transplantation (Table 11). The cynomolgus 
monkeys (Macacafascicularis) weighed 2.3 to 4.1 kg. 
The baboons weighed 8 to 12 kg. Blood types were 
determined, and donor and recipient combinations 
were made to ensure blood type compatibility. Cytotox-
ic crossmatches between donors and recipients were 
determined with conventional crossmatch techniques. 
Anesthesia was induced by an intramuscular injection 
of 10 mg/kg of ketamine. Animals were intubated and 
ventilated with a mixture of oxygen, nitrous oxide, and 
halothane. Renal allografts were placed intra-abdomi-
nally, and end-to-side anastomoses were performed 
between the renal artery and the abdominal aorta and 
between the renal vein and the inferior vena cava. The 
native kidneys of the recipients were removed. Ureter-
oneocystostomy was performed. One gram of cephalo-
sporin was given daily for 3 days. Diet was resumed on 
the first postoperative day. 
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Table II. Primate experimental groups* 
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Oral FKf dose Postop days of 1M FK dose Postop days of 
Group n (mg/kg/day) oral FK dose (mg/kg/day) 1M FK dose 
Renal transplantation in cynomolgus monkeys 
A 3 
·B 3 0.3 1 onward 
C 2 0.3 1 onward 1.0 14,15,16 
Renal transplantation in baboons 
D 4 
E 4 2.0 4 onward 0.5 1-3 
F 3 6.0 4 onward 1.0 1-3 
Toxicology in baboons (nonop) 
G 4 
H 6 1.0 30 days (no 
operation) 
Legend: 1M, Intramuscular. 
·Therapy stopped after 90 days in survivors. 
tThere were four technical failures (artery thromboses) in the tiny cynomolgus monkeys and two technical failures in the baboons. These animals are not included in the 
data. 
Table III. Summary of dose-effectiveness study in canine renal transplantation 
Latest biochemistry! 
Histologic severity of Total 
Survival 
graft rejectionf Creatinine AST bilirubin Glucose FK blood level§ 
Group Treatment days * 0 2 3 (mg/dl) (IU/L) (mg/dl) (mg/dl) (ng/ml) 
Untreated 13.0±4.1 0 0 0 6/6 11.3 ± 35 ± 15 0.2 ± 0.2 105 ± 66 
control 3.1 
2 FK,0.5 33.7 ± 23.9 0 1/5 2/5 2/5 7.7 ± 5.3 79 ± 47 0.4 ± 0.3 143 ± 32 0.44 ± 0.57 
mg/kg/day 
3 FK,1.0 31.0 ± 18.4 1/6 0 3/6 2/6 2.8 ± 1.8 26 ± 6 0.4 ± 0.4 128 ± 30 0.68 ± 0.25 
mg/kg/day 
4 FK, 1.5 61.0 ± 33.6 1/3 1/3 0 1/3 3.0 ± 3.0 37 ± 17 0.9 ± 0.7 98 ± 29 0.40 ± 0.41 
mg/kg/day 
5 FK,2.0 32.1 ± 33.9 5/5 0 0 0 1.4 ± 0.5 55 ± 28 1.2 ± 1.4 79 ± 37 3.92 ± 4.01 
mg/kg/day 
Legend: AST, Aspartate aminotransferase. 
·Used 90 days as a ceiling of calculation. 
tGrafts from animals that lived for more than 90 days are excluded, 0 (none), 1 (mild), 2 (moderate), and 3 (severe). 
:t:Values from the latest measurement or at the ninetieth day. 
§By enzyme immunoassay with monoclonal antibody. 
Drug administration 
FK 506 for oral or intramuscular use was supplied 
as powder by the Fujisawa Pharmaceutical Co., Ltd., 
Osaka, Japan. The oral doses were placed in commer-
cial gelatin capsules and the intramuscular doses were 
suspended in normal saline solution. In the experi-
ments involving transplantation, the extent of intra-
muscular administration varied from exclusive in the 
canine liver experiments, through temporary with 
baboons, to never in most of the series (Tables I and 
II). 
Assurance of swallowing in dogs was by digital 
insertion of the capsule at the pharyngoesophageal 
junction. For the cynomolgus monkeys, FK was mixed 
with fruit paste during the first several days after the 
operation or dispersed onto pieces of fruit thereafter. 
Complete acceptance of the FK was carefully moni-
tored face to face.' The baboons readily ate fruit that 
was impregnated with FK. When the baboons were 
weak or hesitated to take diet, FK was suspended in 20 
ml of normal saline solution and administered through 
the gastric tube under anesthesia with 5 mg/kg of 
intramuscular ketamine. 
Cyclosporine was given in the commercial oil carrier 
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Fig. 1. Serum creatinine concentration and FK plasma 
levels in dogs that lived the longest in the dogs of groups 2 
through 5 treated with different daily doses of FK 506. 
that is used clinically. Prednisone was given orally to 
dogs in 5 mg tablets. To prevent vomiting in the dog 
caused by FK or other postoperative factors, 2 mg of 
atropine sulfate was given intramuscularly twice a day 
for the first postoperative week and once a day for the 
second postoperative week. The dose of atropine was 
reduced to 1 mg once a day during the third postoper-
ative week. Monkeys and baboons did not vomit; thus 
atropine administration was unnecessary. 
Biochemical and pathologic studies 
Blood samples were taken every 3 mornings in the 
dog and once a week in the subhuman primates for the 
measurement of blood urea nitrogen, creatinine, aspar-
tate aminotransferase, total bilirubin, glucose, and 
white blood cells, red blood cells, and platelets. Hepa-
rinized blood samples for plasma FK and whole blood 
cyclosporine measurements were collected, centrifuged, 
and stored frozen until the analyses. FK plasma levels 
were measured by enzyme immunoassayl4 with mono-
clonal or polyclonal antibody to FK. Cyclosporine level 
was measured with whole blood by high-performance 
liquid chromatography using cyclosporine D as an 
internal standard.15 
When an animal died or was killed, complete 
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postmortem examination was performed immediately. 
Tissues were fixed with formalin, paraffin embedded, 
and stained with hematoxylin-eosin or with special 
techniques as indicated. Histopathologic changes were 
scored blindly according to subjective scales from 0 to 3. 
All tissues were examined blindly without knowledge 
of the postoperative course, type, or dosage of immuno-
suppressive therapy or length of survival. 
Statistics 
The values were described as the mean ± SD. The 
Mann-Whitney V test, X2 test, and Student t test were 
applied for the statistical analyses, with which the 
difference of group means was considered significant if 
the probability of error was less than 0.05 . 
RESULTS 
Canine experiments 
Chronic FK alone for kidney transplantation 
SURVIVAL AND REJECTION. Compared with that of 
untreated controls in group 1, survival was significant-
ly improved with all oral daily doses of FK from 0.5 to 
2 mg/kg (Table III). The best results were with 1.5 mg 
(p < 0.01); three of six dogs (group 4) lived for 90 days, 
and the mean survival was 61 ± 33.6 (SD) days. With 
daily doses lower than this, biochemical and histopath-
ologic evidence of rejection became common (Table 
III). At the higher dose of 2 mg/kg/day, rejection was 
completely avoided, but four of six animals died of 
intussusception after 8, 8, 10, and 20 days. One of the 
other dogs lived for 57 days and the sixth dog is alive 
after 250 days, 5Y2 months after discontinuation of 
treatment. 
PLASMA FK LEVELS. With the monoclonal assay, the 
trough plasma levels from the last specimen collected 
were not different in groups 2, 3, and 4, but were 
elevated to an average of nearly 4 ng/ml in group 5 
(p < 0.05). The highest levels were 7.6 ng/ml in a dog 
that died with jaundice after 57 days and 10.1 ng/ml in 
a dog that died of intussusception after 10 days. 
The possibility that much lower levels could be 
therapeutic was suggested by more complete data in the 
longest surviving dogs in each of groups 2 through 5. In 
these animals trough levels in samples stored through-
out the course of therapy reflected, although inexactly, 
the oral doses and were never higher than 0.5 ng/ml 
(Fig. 1). All of the foregoing analyses were performed 
in Japan by those who had invented the technique and 
were experts in the monoclonal technique. 14 
There was no correlation between plasma levels and 
liver functions or blood glucose concentrations (Table 
III) with the possible exception of the single dog in 
group 5 that had terminal jaundice. There was no 
evidence whatever of bone marrow depression as 
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Fig. 2. Survival in dogs receiving multiple drug treatment with FK 506, cyclosporine, and prednisone, along 
with control experiments. (See text for details.) 
judged by peripheral white cell, platelet, or red cell 
measures. 
TOLERANCE INDUCTION. Three of six animals in group 
4 lived after the discontinuation of FK at 90 days, but 
died at 98, 130, and 133 days after transplantation. In 
contrast, the single survivor from high-dose group 5 
seemed tolerant after drug stoppage and still has 
perfect renal function 250 days after transplantation. 
Drug combinations for kidney transplantation 
SURVIVAL AND REJECTION. With daily doses of 0.5 
mg/kg of FK, 5 mg/kg of cyclosporine, and 5 mg of 
prednisone (group 6), five (83%) of six recipients lived 
until the treatment was stopped at 90 days (Fig. 2). 
The only death was after 23 postoperative days from 
emaciation and pancreatitis. Although the creatinine 
level was 3.2 mg/dl, the kidney showed no histopatho-
logic evidence of rejection. Omission of the prednisone 
(group 8), cyclosporine (group 9), or FK (group 10) 
from the triple drug formula or reduction of the triple 
drug doses by half (group 7) reduced survival 
(Fig. 2). 
If only two drugs were used, the best combination 
was FK and cyclosporine, with a mean survival of 
54.3 ± 39.4 (SD) days. One animal from this group 
died of intussusception after 12 days, one other died of 
rejection at day 17, and the third died of unknown 
causes at 27 days. The other three animals in group 8 
lived for 90 days. 
Individually, FK, cyclosporine, and prednisone pro-
vided mean survival of 33.7, 18, and 13.8 days, 
respectively (Fig. 2). 
Except in groups 6 and 8, uncontrolled rejection was 
the cause of death in almost all of the dogs. 
PLASMA FK AND BLOOD CYCLOSPORINE LEVELS. A 24-hour 
trough level of plasma FK was measured in each of the 
24 animals in groups 6 through 9 from 12 to 90 days 
after surgery. The blood samples were the last ones 
collected from each dog and thus were obtained from a 
week to 3 months after surgery. The FK concentrations 
were 0.51 ± 0.38 (SD) ng/ml (range, 0.02 to 1.39). 
There were no significant differences in plasma levels 
between groups, nor was there any correlation with 
survival. 
The 24-hour trough levels of blood cyclosporine 
measured with the high-performance liquid chroma-
tography technique in the animals of groups 6, 7, 8, 10, 
and 11 were less than 50 ng/ml in every case and 
usually undetectable. From other work in our labora-
tory such levels have been thought to be suboptimal or 
even homeopathic. 16 
TOLERANCE INDUCTION. Nine dogs lived for 90 days 
until discontinuation of medication, five from group 6, 
three from group 8, and one from group 10. However, 
all five survivors from group 6 died soon after 90 days. 
Rejection was the cause of death after a total posttrans-
plant survival time of 98, 100, 103, 114, and 120 days. 
Two of the three dogs from group 8 that survived for 3 
months died of rejection after 129 and 162 days, but the 
third is well after 237 days. One dog treated with 
cyclosporine and prednisone (group 10) is in good 
health after 258 days. 
FK bolus therapy intramuscularly 
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Table IV. Prolongation of graft survival by FK bolus therapy 
FK, 1 mg/kg/day, 1M 
Transplantation Group (on postop days) Survival days p Valuef 
Kidney None 8, 9, 12, 14, 17, 18 
13 1-3 21,19,32,35,42,69 <0.003 
14 4-6 42,49,51, >198 <0.01 
15 7-9 11,27,36,39,42,49 <0.02 
16 4, 5, 6, 31, and 32 46,66,67 <0.02 
Liver 
Legend: 1M, Intramuscular. 
'Data from Ref. 16. 
* 
17 
18 
tBy the Mann-Whitney test vs the nontreatment group. 
None 6,6,7,7; 7,19,35 
4-6 58, 72, >160 <0.02 
4-6 24,28, >51, ±52 <0.02 
Table V. Summary of renal transplantation in cynomolgus monkeys 
Group Treatment No. 
A Untreated 757 
controls 852 
844 
B FK,0.3 719 
mg/kg/day 750 
753 
C FK,0.3 
mg/kg/ 724 
day, po 
FK,1 755 
mg/kg/ 
day, 1M, 
at days 
14-16 
Survival 
(days) 
8 
10 
7 
8 
9 
10 
94 
96 
Severity of 
graft rejection 
(histopathology) 
Not done 
Mild to 
moderate 
Mild to 
moderate 
Severe 
Mild to 
moderate 
Severe 
Severe 
Severe 
Legend: AST, Aspartate aminotransferase; po, by mouth; 1M, intramuscular. 
'Values from the latest blood samples or at the ninetieth day. 
RENAL TRANSPLANTATION. Survival of mongrel grafts 
in beagle recipients was remarkably prolonged with 
three doses only of 1 mg/kg of intramuscular FK on 
days 1 to 3, or days 4 to 6, or even on days 7 to 9 when 
rejection should have been well established (Table IV). 
One of the animals treated on days 4 through 6 (group 
14) is now 202 days postoperative but all others 
rejected their kidneys. 
Three beagle dogs treated on days 4 to 6 developed 
signs of rejection of their mongrel grafts at 1 month and 
were rescued for 2 to 5 additional weeks with two 
additional single injections (group 16)_ 
Latest biochemistry * 
Total 
Creatinine AST bilirubin Glucose FK 
(mg/ml) (IU/L) (mg/dl) (mg/dl) (ng/ml) 
16_7 696 0_5 156 
12.9 102 0.2 63 
9.9 342 0.7 227 
35.5 600 0.6 187 
34.9 66 0.3 77 
18.9 145 0.6 194 
3_0 21 0_2 50 0.4 
4.5 19 0.2 61 3.0 
LIVER TRANSPLANTATION. Seven dogs had intramuscu-
lar FK on postoperative days 4, 5, and 6. Three of these 
beagle recipients were given livers from beagle donors 
(group 17); two lived for 58 and 72 days before dying of 
rejection and the third is well after 5yz months. The 
other four beagle were given mongrel livers (group 18). 
Two dogs died at 24 and 28 days whereas the other two 
are living after 51 and 52 days (Table IV). 
Subhuman primate experiments 
Renal transplantation 
CYNOMOLGUS MONKEYS. Three untreated animals died 
of rejection after 7, 8, and 10 days (Table V). Oral 
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Fig. 3. Clinical course of two cynomolgus monkeys that 
lived for more than 90 days under FK treatment. One 
monkey (No. 724) is shown by solid lines and open 
column, and the other (No. 755) is shown by dotted lines and 
black column. The FK plasma levels were not measured 
during the first 2 months. 
treatment of five recipients with 0.3 mg/kg/ day of FK 
(groups B and C) did not dramatically modify the 
initial course. Three of the monkeys without augment-
ed treatment (group B) died, but the other two (group 
C) that were given an additional 1 mg/kg/day of 
intramuscular FK for 3 days on days 14, 15, and 16 
lived for 3 months. These monkeys died after 94 and 96 
days, a few days after discontinuation of maintenance 
FK. 
The course of the latter two animals is summarized 
in Fig. 3. During the third postoperative month, FK 
plasma levels ranged from 0.4 to 3 ng/ml as measured 
in the Pittsburgh laboratories with a polyclonal anti-
FK antibody.14 
All of the kidney losses, early or late, were from 
rejection (Table V). 
BABOONS. Four untreated baboons (group D) rejected 
their kidneys after 5 to 14 days (Table VI). Two 
baboons treated with what were considered large doses 
of intramuscular and oral FK every 12 hours also 
rejected their kidneys after 14 and 18 days (group E). 
When the intramuscular dose was doubled and the oral 
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Fig. 4 Clinical course of a baboon that is alive more than 50 
days after transplantation under FK treatment. 
dose was tripled (group F), one of three baboons 
survived a bout of early renal failure and has a 
creatinine level of 1.8 mg/dl after 46 days. The other 
two developed renal failure and died (Table VI), but 
the histopathologic findings of rejection were rather 
mild. 
With the polyclonal enzyme immunoassay, the 12-
hour trough levels of plasma FK in the treated baboons 
were 2 to 5 ng/ml at the time of the last blood samples 
(Table VI). The 12-hour trough levels in the surviving 
baboon are shown in Fig. 4. 
Unoperated baboons 
Four baboons were killed after a month for tissues, 
and the other six were given 1 mg/kg/day of FK for 30 
days before death. One of the latter six animals lost 
weight, three maintained their weight, and two actual-
ly gained weight. This performance was similar to that 
of the four control baboons that were given placebos. 
The treated animals were healthy throughout despite 
the fact that three were found to be malaria carriers. 
Major changes in blood sugars, liver chemistries, and 
hematologic studies were not seen during treatment. 
Major toxic effects were not found with histopathologic 
study. These toxicology studies will be reported sepa-
rately, as well as the pharmacokinetic data obtained. 
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Table VI. Summary of renal transplantation in baboons 
Survival 
Group Treatment No. (Days) 
D Untreated controls 87 11 
E FK,0.5 
mg/kg/day 1M, 
for 3 
days + FK, 2.0 
mg/kg/day, po, 
from days 4 
onward 
F FK, 1.0 mg/day 
1M, for 3 days, 
+ FK, 6 mg/kg 
po, from day 4 
onward 
90 7 
106 
112 
95 
97 
104 
107 
110 
5 
14 
14 
18 
23 
>45 
7 
Severity of 
graft rejection 
(histopathology) 
Severe 
Moderate to 
severe 
Mild to 
moderate 
Severe 
Moderate 
Severe 
Severe 
Mild 
Legend: AST, Aspartate aminotransferase; 1M, intramuscular; po, by mouth. 
'Values from the latest blood samples or at the ninetieth day. 
Host tissue pathology 
The clear and dose-dependent immunosuppressive 
effect of FK was described under the individual groups 
and is partially summarized in Table III. Host tissues 
were also examined blindly with the same technique 
without knowledge of the experiment. 
Dogs. As the doses of FK were increased, pathologic 
changes in the non-transplanted organs began to 
appear. These changes included pancreatic acinar cell 
degeneration and degranulation, fine isometric vacuoli-
zation of the proximal tubules of the kidney (in liver 
transplant experiments), and prominent centrilobular 
hepatocellular swelling and cholestasis (in kidney 
transplant experiments) similar to that observed with 
erythromycin toxicity in humans. These presumed 
toxic effects were present to some degree in all dogs 
receiving 2.0 mg/kg of FK 506 orally, had a variable 
presence in intermediate doses, but were not present in 
any of the control animals. Similar histologic findings 
have been detected (unpublished observations) in 
straight toxicologic studies in dogs. 
Severe fibrinoid medial necrosis of medium-sized 
arteries was detected in virtually all organs, but was 
Creatinine 
(mg/ml) 
24.3 
16.5 
14.2 
13.0 
19.3 
17.5 
23.3 
1.8 
14.4 
AST 
(IU/L) 
42 
193 
45 
51 
52 
48 
68 
27 
63 
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Latest biochemistry* 
Total 
bilirubin 
(mg/dl) 
0.5 
1.0 
1.5 
0.8 
1.4 
1.7 
0.5 
0.5 
0.5 
Glucose 
(mg/dl) 
198 
95 
82 
93 
122 
256 
93 
97 
109 
FK 
(ng/ml) 
206 
202 
4.90 
2.10 
3.83 
particularly noticeable in the gastrointestinal tract and 
heart. Nearby focal parenchymal ischemic necrosis was 
seen. Initially, we assumed that the arteritis repre-
sented a toxic side effect of FK in the dogs as reported 
by Thiru et alY and Collier. to However, after breaking 
the blinded code analysis of the slides, we discovered 
that the arteritis was found in control animals with 
equal frequency and severity. 
Monkeys. No hepatocellular swelling such as that 
observed in dogs was detected. After kidney transplan-
tation, a severe necrotizing arteritis was detected in the 
extrarenal organs of monkeys given FK, but this was 
present with equal frequency and severity in the 
untreated control animals. 
Baboons. In the baboons undergoing transplanta-
tion, hepatocellular swelling was not seen. Arteritis 
was not observed in any of the animals contributing to 
the definitive experiments. Necrotizing arteritis in the 
intestine was seen in one baboon that died 4 days after 
surgery of a hemorrhage from the ligated renal pedicle 
and was omitted from data analysis. 
The untransplanted baboons of the toxicology study 
did not have arteritis or hepatocellular swelling. There 
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Table VII. Histopathologic abnormality of extrarenal organs from dogs, monkeys, and baboons* 
Heart: Necrotizing 
arteritis Pancreas: Gastrointestinal 
micromyocardial Liver: Hepatocellular Acinar tract: necrotizing 
Treatment Groupst infarction swelling, cholestasis cell degeneration arteritis Animal 
Control +++ ++ 
FK 2-5 +++ + ++ +++ 
Dog 
FK in 6-9 + + + + 
combination 
Monkey Control A ++ + 
FK B,C ++ + 
Baboons Control D 
FK E,F + 
Toxicology G 
H + 
·Abnormalities are classified as follows: (-) none, (+) mild, (++) moderate, and (+++) severe. 
tFor details, see text. 
was exocrine degranulation in. the pancreas and 
increased cell turnover. The hyperglycemia described 
in rats by N alesnik et al. 18 and in baboons by CaIne et 
alY was not found in our baboons. The lack of side 
effects in the baboons suggested that the toxicity of FK 
differs along species lines (Table VII). 
DISCUSSION 
A much clearer picture has emerged from these 
studies of the potential clinical value of FK 506 and the 
conditions that will permit its most effective and safe 
use. The practicality of combining FK with other 
conventional agents was evident in the canine experi-
ments. The results obtained with subtherapeutic doses 
of FK, cyclosporine, and steroids were as good within a 
90-day time frame as have ever been reported in dogs 
with any drug regimen. 
The concept of drug synergism for immunosuppres-
sion is an old one,t9 but difficult to prove until recently. 
Now, the interaction of drugs can be studied with great 
precision by measuring their effect on mixed lympho-
cyte culture systems. Using such in vitro "mini-
transplant" models, Sawada et al. 20 and Zeevi et al. 21 
showed striking synergism of FK and cyclosporine. 
The same has been seen equally clearly with heterotop-
ic heart transplantation in rats.9 The synergism of FK 
and cyclosporine is of special interest, since the two 
drugs have similar, if not identical, actions4,22 and may 
even compete for the same binding sites.23 Our previous 
belief that synergism would depend on differing mech-
anisms of the individual components of a drug cocktail 
was probably erroneous. 
It is fortunate that immunosuppression can be 
enhanced with drug combinations without a parallel 
enhancement of toxicity. The dog was chosen for the 
drug combination studies because of the reported 
inability of this species to tolerate FK. 7,8,10,17 
There is little doubt that dogs can be made violently 
ill with large doses of oral or intramuscular FK 506. 
The histopathologic changes in the liver and pancreas 
might be a clue to the pathogenesis of these events. 
Ironically, the most publicized side effect of FK 506, 
namely, widespread arteritis, may not actually be 
attributable to this agent. The carefully controlled 
histopathologic analyses in our investigation, in which 
the readings were decoded after the analyses were 
completed, revealed the same distribution and severity 
of arteritis in untreated control dogs as in those given 
FK, cyclosporine, or steroids, or any combination of 
these agents. The same applied to the cynomolgus 
monkeys. 
In contrast, arteritis was not seen in the baboons that 
were also singularly free of the hepatocyte swelling and 
pancreatic lesions characteristic of the dog. Although 
CaIne et aUI have reported alarming side effects of FK 
in baboons, we have concluded that the safety of FK in 
baboons is equivalent to that in rats.9,18 
However, final judgment must be deferred pending 
definitive studies of FK pharmacokinetics. Preliminary 
results (unpublished observations) indicate that the 
half-life of FK 506 is about 6.3 hours in baboons 
compared with 6.1 hours in dogs, as measured with 
polyclonal antibodies. Since an intravenous dosage of 
FK 506 is currently unavailable, it is not possible to 
determine directly whether the extent of absorption of 
FK 506 is different between dogs and baboons. So far, 
decisive information has not been obtained regarding 
the correlation in any species of plasma levels of FK 
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with either toxicity or immunosuppression. Interpreta-
tion of the results was made difficult by mixing the use 
of monoclonal and polyclonal assay techniques and 
with the further disadvantage that these assays that are 
still being perfected were done in Pittsburgh and 
Japanese laboratories half a world apart. Seemingly 
effective blood levels in dogs, monkeys, and baboons 
were as low as 0.2 ng/ml or higher than this by a factor 
of 40. It could not even be determined from the data so 
far obtained if the pharmacokinetics of FK in dogs and 
subhuman primates were fundamentally different. 
In our monkey and baboon transplant experiments, 
mitigation of rejection was unequivocally demon-
strated, but the effect was limited. The explanation 
could include underdosing with FK, poor alimentary 
absorption in the oral administration experiments, or 
species-specific peculiarities in the metabolism of the 
drug. All of these ambiguities will be clarified prompt-
ly once the monoclonal assay technique is standardized 
and stored samples are analyzed from experiments 
already completed. 
For the past 25 years, clinical organ transplantation 
has depended on the daily or twice daily administration 
of immunosuppressive drugs, presumably for a life-
time. Discontinuation of treatment is usually followed 
by rejection. This was seen in 10 of the 13 canine and 
both of the cynomolgus renal recipients whose treat-
ment was stopped after 90 days. In three dogs, toler-
ance, or something resembling this condition, was 
accidentally produced but so unreliably and unpredict-
ably that it was of no practical value. 
Because further work with FK is planned, thought 
should be given to the alternative of providing a short 
course of high-dose treatment. The striking effect of a 
short course of moderately high-dose FK therapy 
intramuscularly was particularly striking with both 
canine renal and hepatic transplantation. Three days of 
treatment, even as late as 7, 8, and 9 days after 
transplantation, far outlasted the intramuscular injec-
tions. Although the grafts were not accepted perma-
nently, the results were as good or better than with 
almost all of the variations of long-term multiple drug 
therapy. The only other agent that has ever allowed 
extended homograft survival in dogs with such a short 
period of perioperative treatment has been antilympho-
cyte serum or its globulin derivative (antilymphocyte 
globulin).24 
We are grateful to the exploratory research laboratories, 
Fujisawa Pharmaceutical Co., Ltd., Dr. A. Sanghvi, Dr. V. 
Warty, and Dr. Evan Cadoff, for measuring FK blood level, 
and Dr. A. Zeevi, Dr. R. Duquesnoy, and Dr. J. Falk for 
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performing cytotoxic crossmatches in subhuman primates. 
All of these colleagues also provided advice and encourage-
ment throughout the study, as did numerous other members 
of the surgery, pathology, and medical departments at the 
University of Pittsburgh. 
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DISCUSSION 
Dr. Richard Wood (London, England). Although FR 506 
is a potentially exciting immunosuppressive agent, it appears 
to cause hyperglyemia. Cyclosporine and steroids in high 
doses also cause this problem. Therefore in addition to the 
synergy in treating rejection that you have observed, is there 
also synergy in the development of hyperglycemia when FR 
506 is used in combination with cyclosporine and steroids? 
Immunosuppression with FK 506 249 
Dr. Hockerstedt (Helsinki, Finland). Do you have any 
results on the effect of FK on the liver? I do not mean 
transaminase changes; I would like to hear some histologic 
results because other groups have found really adverse side 
effects on the liver. Why do you continue to use a rather low 
dose of cyclosporine in the control dogs. In group 9, cyclo-
sporine and prednisone, there really was no difference in 
survival with the nontreatment group with the exception of 
one dog, and I am sure that none of us would start to use 
cyclosporine with these results. 
Dr. Todo (closing). Dr. Wood, we know that the Cam-
bridge group claimed that this drug induced hyperglycemia. 
Actually, only one dog died with hyperglycemia on the 
twenty-third day of treatment with a single FK drug (2 
mg/kg). This dog had pancreatitis as well as mild jaundice, 
but other than that, we did not see any significant correlations 
with the dose of FK and hyperglycemia. The glucose levels in 
the monkeys and baboons are almost stable, 100 mg/dl, 
throughout the treat11lent. However, in the rats, treated with 
an oral dose of 4/mg of FK for 1 month, there was an 
elevation in glucose level, but this was very minor. 
The second·question regarding changes in the liver, central 
local hepacyte swelling occurred in dogs but not in the rats or 
monkeys. 
Dr. Hockerstedt, regarding the continuous low-dose use of 
cyclosporine, our system was to have a treatment baseline 
that was not effective to which low doses of FK could be 
added. We were testing a possible strategy for clinical trials. 
We know that if we stop cyclosporine, or lower the dose, in 
patients, we frequently see rejection. 
Editors' note: This article contains more material than this 
Discussion addressed. 
